Profile data is unavailable for this security.
About the company
Moderna, Inc. is a biotechnology company. The Company is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range spectrum of diseases. The Company's products include Spikevax, the Moderna COVID-19 vaccine (mRNA-1273), a bivalent vaccine targeting the BA.1 Omicron variant, combined with Spikevax (mRNA-1273.214), and bivalent vaccine targeting the BA.4/BA.5 Omicron variants combined with Spikevax (mRNA-1273.222). It has a development pipeline of 45 development candidates across its 48 development programs, of which 38 are in clinical studies.
- Revenue in USD (TTM)19.26bn
- Net income in USD8.36bn
- Incorporated2016
- Employees3.90k
- LocationModerna Inc200 Technology SqCambridge 02139-3578United StatesUSA
- Phone+1 (617) 714-6500
- Fax+1 (617) 583-1998
- Websitehttps://www.modernatx.com/
Mergers & acquisitions
| Acquired company | MRNA:NSQ since announced | Transaction value |
|---|---|---|
| OriCiro Genomics KK | -17.92% | 85.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DuPont de Nemours Inc | 13.02bn | 1.01bn | 31.89bn | 23.00k | 34.58 | 1.20 | 14.52 | 2.45 | 2.01 | 12.09 | 26.06 | 58.00 | 0.299 | 3.81 | 5.57 | 565,956.50 | 2.44 | 0.2193 | 2.74 | 0.2889 | 35.45 | 34.76 | 8.15 | 1.44 | 2.40 | 5.80 | 0.2301 | 840.00 | 3.59 | 2.21 | -12.68 | -- | -27.68 | 2.98 |
| Iqvia Holdings Inc | 14.41bn | 1.09bn | 35.34bn | 86.00k | 33.20 | 6.12 | 15.83 | 2.45 | 5.72 | 5.72 | 75.60 | 31.04 | 0.5761 | -- | 5.27 | 167,558.10 | 4.41 | 2.38 | 5.63 | 2.94 | 34.89 | 34.32 | 7.65 | 4.64 | -- | 4.53 | 0.6886 | 0.00 | 3.86 | 8.23 | 12.94 | 28.53 | 12.80 | -- |
| Seagen Inc | 1.96bn | -610.31m | 37.99bn | 3.26k | -- | 13.51 | -- | 19.36 | -3.30 | -3.30 | 10.63 | 15.03 | 0.5308 | 1.31 | 4.40 | 602,706.40 | -16.51 | -7.68 | -20.32 | -8.94 | 79.10 | 85.29 | -31.10 | -14.45 | 2.90 | -- | 0.00 | -- | 24.65 | 32.40 | 9.51 | -- | 21.91 | -- |
| Moderna Inc | 19.26bn | 8.36bn | 56.66bn | 3.90k | 7.36 | 2.96 | 6.51 | 2.94 | 19.96 | 19.96 | 46.31 | 49.67 | 0.7625 | 4.53 | 8.45 | 4,939,231.00 | 33.10 | 38.59 | 45.85 | 58.05 | 71.88 | -- | 43.41 | 48.84 | 2.54 | -- | 0.0531 | 0.00 | 4.29 | 147.88 | -31.47 | -- | 46.94 | -- |
| Zoetis Inc | 8.08bn | 2.11bn | 76.48bn | 13.80k | 36.72 | 17.38 | 29.69 | 9.47 | 4.49 | 4.49 | 17.19 | 9.50 | 0.5606 | 1.14 | 6.88 | 585,507.30 | 14.65 | 14.06 | 17.69 | 16.51 | 69.78 | 69.29 | 26.13 | 25.02 | 1.63 | 12.68 | 0.6422 | 24.62 | 3.91 | 8.77 | 3.78 | 14.46 | 21.21 | 24.14 |
| Vertex Pharmaceuticals Incorporated | 8.93bn | 3.32bn | 80.53bn | 4.80k | 24.44 | 5.79 | 23.21 | 9.02 | 12.82 | 12.82 | 34.47 | 54.13 | 0.5655 | 2.66 | 6.93 | 1,860,563.00 | 21.04 | 19.92 | 24.88 | 23.81 | 87.90 | 87.71 | 37.20 | 33.69 | 4.66 | 72.86 | 0.03 | 0.00 | 17.91 | 29.12 | 41.84 | 66.04 | -4.63 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Dec 2022 | 44.79m | 11.66% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 25.91m | 6.75% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 17.29m | 4.50% |
| SSgA Funds Management, Inc.as of 31 Dec 2022 | 14.30m | 3.72% |
| Coatue Management LLCas of 31 Dec 2022 | 6.39m | 1.66% |
| Geode Capital Management LLCas of 31 Dec 2022 | 6.17m | 1.61% |
| Th�l�me Partners LLPas of 31 Dec 2022 | 5.86m | 1.53% |
| Wellington Management Co. LLPas of 31 Dec 2022 | 4.28m | 1.11% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2022 | 3.90m | 1.02% |
| Norges Bank Investment Managementas of 31 Dec 2022 | 3.50m | 0.91% |
